Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Statin, Acetylsalicylic Acid and Dutasteride Use in Prostate Cancer

This study has been completed.
Information provided by (Responsible Party):
University Health Network, Toronto Identifier:
First received: August 26, 2011
Last updated: September 8, 2011
Last verified: September 2011

The purpose of this study is to assess whether there is any interaction between statins, acetylsalicylic acid (ASA) and dutasteride on protection from prostate cancer, the development of high grade prostate cancer, or lower urinary tract symptoms.

Prostate Cancer

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: The Effect of Combination Statin, Acetylsalicylic Acid and Dutasteride Use on Prostate Cancer - a Sub Analysis of the REDUCE Trial

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Diagnosis of Prostate Cancer [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    The relative risk of prostate cancer development in REDUCE study participants treated with a combination of statins, acetylsalicylic acid and dutasteride.

Secondary Outcome Measures:
  • Diagnosis of High Grade Prostate Cancer [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    The relative risk of high grade prostate cancer development in REDUCE study participants treated with a combination of statins, acetylsalicylic acid and dutasteride

  • Improvement of Lower Urinary Tract Symptoms [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    The impact of combination statin, acetylsalicylic acid and dutasteride use on lower urinary tract symptoms in REDUCE study participants.

Biospecimen Retention:   Samples Without DNA

Specimens were retained as part of the REDUCE protocol, but no biospecimens are required for the current protocol.

Enrollment: 8231
Study Start Date: August 2011
Study Completion Date: August 2011

Detailed Description:

A review of data collected from REDUCE (REduction by DUtasteride of prostate Cancer Events) study participants will be performed. Data required for the analysis includes: ethnicity, prostate specific antigen (PSA) levels, prostate volumes, presence of diabetes, concomitant medication use (for statin and ASA), prostate biopsy results at 2 and 4 years, body mass index (BMI), digital rectal exam (DRE) results, family history of Prostate Cancer and benign prostatic hyperplasia (BPH) outcomes: urinary retention, international prostate symptom score (IPSS), urinary tract infections (UTI)s.

The association of drug interactions with prostate cancer will be explored by using a multivariate logistic regression model including all possible interaction terms between dutasteride, ASA and statins (i.e. statin+ASA+dutasteride, statin+ASA, dutasteride+statin, dutasteride+ASA). Any interaction term found to be insignificant ( i.e. p>0.05) will be removed from the model. If a statistically significant interaction term is identified, the study cohort will be stratified by drug use, and the relative risk (RR)of prostate cancer among the different drug users will be reported. To control for potential confounders, a multivariate regression model will be constructed adjusting for age, family history of prostate cancer, DRE results and BMI.


Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Participants of the REDUCE trial (negative prostate biopsy at baseline) who had at least one post-baseline prostate biopsy.


Inclusion Criteria:

  • Participants who received dutasteride or placebo and had at least one post-baseline prostate biopsy

Exclusion Criteria:

  • Participants not taking concomitant statins or ASA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01428869

Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University Health Network, Toronto
Principal Investigator: Neil E Fleshner, MD MPH FRCSC University Health Network, Toronto
  More Information

No publications provided

Responsible Party: University Health Network, Toronto Identifier: NCT01428869     History of Changes
Other Study ID Numbers: 10-1000AE
Study First Received: August 26, 2011
Last Updated: September 8, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by University Health Network, Toronto:
acetylsalicylic acid
Prostate Cancer
Lower urinary tract symptoms
drug interactions

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Hydroxymethylglutaryl-CoA Reductase Inhibitors
5-alpha Reductase Inhibitors
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Anticholesteremic Agents
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents processed this record on November 20, 2014